Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Cocaine-Related Disorders · Cocaine Dependence · DRUG

BRIGHT MINDS BIOSCIENCES

BRIGHT MINDS BIOSCIENCES INC.

BRIGHT MINDS BIOSCIENCES clinical programs — 327 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
19 Vestry St, New York, NY 10013, US HQ
12 Employees
Public company Type
DRUG · NYSE Ticker
Company details
Status
Public
HQ
19 Vestry St, New York, NY 10013, US
Employees
12
Programs
1063
Drugs
444
Patents
57
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

BRIGHT MINDS BIOSCIENCES projects

327 ClinicalTrials.gov programs sponsored by BRIGHT MINDS BIOSCIENCES.

BRIGHT MINDS BIOSCIENCES has 327 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

327 programs

Clinical programs

Page 6 of 7

  1. RAD 001 in combination with Caelyx

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  2. RDC-0313 + Buprenorphine

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 1 small molecule completed

    1 trial

  3. RTI-336

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine Dependence

    phase 1 small molecule terminated

    1 trial

  4. Radiolabelled Diclofenac Tablet A

    BRIGHT MINDS BIOSCIENCES INC.

    Pain

    phase 1 small molecule completed

    1 trial

  5. Radiolabelled T4 Tablet

    BRIGHT MINDS BIOSCIENCES INC.

    Pain

    phase 1 small molecule completed

    1 trial

  6. Ranolazine

    BRIGHT MINDS BIOSCIENCES INC.

    Drug-induced QT Prolongation

    phase 1 small molecule completed

    1 trial

  7. Repetitive Transcranial Magnetic Stimulation

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Use

    phase 1 other terminated

    1 trial

  8. Research ENDS S-TA-U001

    BRIGHT MINDS BIOSCIENCES INC.

    Cigarette Smoking

    phase 1 small molecule completed

    1 trial

  9. Reserpine

    BRIGHT MINDS BIOSCIENCES INC.

    Amphetamine-Related Disorders

    phase 1 small molecule active

    1 trial

  10. SBP-9330

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking Cessation

    phase 1 small molecule completed

    1 trial

  11. SKSD00702

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  12. ST-2427

    BRIGHT MINDS BIOSCIENCES INC.

    Acute, Post-operative Pain

    phase 1 small molecule terminated

    1 trial

  13. ST1968

    BRIGHT MINDS BIOSCIENCES INC.

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  14. STP7 (mavoglurant)

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use Disorder

    phase 1 small molecule completed

    1 trial

  15. STP705

    BRIGHT MINDS BIOSCIENCES INC.

    Hepatocellular Carcinoma

    phase 1 small molecule completed

    1 trial

  16. SXC-2023

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use Disorder

    phase 1 small molecule completed

    1 trial

  17. SYN115

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 1 small molecule completed

    1 trial

  18. SafeMedWaste

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 1 other active

    1 trial

  19. Saline

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Addiction

    phase 1 small molecule completed

    1 trial

  20. Salmeterol

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy

    phase 1 small molecule completed

    1 trial

  21. Sativex(Registered Trademark)

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis

    phase 1 small molecule completed

    1 trial

  22. Satraplatin in combo with vinorelbine

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  23. Spironolactone

    BRIGHT MINDS BIOSCIENCES INC.

    Alcohol Use Disorder

    phase 1 small molecule active

    1 trial

  24. Sporozoite Challenge Model for Plasmodium vivax in Humans

    BRIGHT MINDS BIOSCIENCES INC.

    Malaria, Vivax

    phase 1 mab completed

    1 trial

  25. Standardized Research E-cigarette (SREC)

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking, Cigarette

    phase 1 small molecule active

    1 trial

  26. Suboxone

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-related Disorders

    phase 1 small molecule completed

    1 trial

  27. Sugar Pill

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 1 small molecule completed

    1 trial

  28. Sutezolid

    BRIGHT MINDS BIOSCIENCES INC.

    Tuberculosis

    phase 1 small molecule completed

    1 trial

  29. TBA-354

    BRIGHT MINDS BIOSCIENCES INC.

    Tuberculosis

    phase 1 small molecule completed

    2 trials

  30. TBA-7371

    BRIGHT MINDS BIOSCIENCES INC.

    Tuberculosis

    phase 1 small molecule completed

    1 trial

  31. TBAJ-587

    BRIGHT MINDS BIOSCIENCES INC.

    Tuberculosis

    phase 1 small molecule completed

    1 trial

  32. TBAJ-876

    BRIGHT MINDS BIOSCIENCES INC.

    Pulmonary Disease

    phase 1 small molecule completed

    1 trial

  33. THC

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis

    phase 1 small molecule completed

    1 trial

  34. THC 30mg

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Use

    phase 1 small molecule active

    1 trial

  35. THC High Dose

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Use

    phase 1 small molecule active

    1 trial

  36. TI-0010

    BRIGHT MINDS BIOSCIENCES INC.

    COVID-19

    phase 1 mab active

    1 trial

  37. TMC207

    BRIGHT MINDS BIOSCIENCES INC.

    Tuberculosis

    phase 1 small molecule completed

    1 trial

  38. TMS (MagVenture MagPro 100 with MagOption)

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy Volunteers

    phase 1 other active

    1 trial

  39. TRIN2755

    BRIGHT MINDS BIOSCIENCES INC.

    Neoplasms

    phase 1 small molecule active

    1 trial

  40. Tacrolimus

    BRIGHT MINDS BIOSCIENCES INC.

    Bioequivalence

    phase 1 small molecule completed

    1 trial

  41. Tacrolimus

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy Volunteers

    phase 1 small molecule completed

    2 trials

  42. Test: Favipiravir 200 mg (LOQULAR)

    BRIGHT MINDS BIOSCIENCES INC.

    Bioequivalence

    phase 1 small molecule completed

    1 trial

  43. Therapeutic Workplace Intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Addiction

    phase 1 other completed

    1 trial

  44. Tiotropium

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy

    phase 1 small molecule completed

    1 trial

  45. Transdermal Nicotine Patch

    BRIGHT MINDS BIOSCIENCES INC.

    E-cigarette Use

    phase 1 small molecule active

    1 trial

  46. Treatment as usual (TAU)

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Abuse

    phase 1 other completed

    1 trial

  47. UB-312

    BRIGHT MINDS BIOSCIENCES INC.

    Parkinson's Disease

    phase 1 mab completed

    1 trial

  48. VK4-116

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Dependence

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does BRIGHT MINDS BIOSCIENCES have?

327 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.